Patents by Inventor Rachel Rebecca BARRETT

Rachel Rebecca BARRETT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES
    Publication number: 20240336674
    Abstract: The present invention relates to antibodies and fragments thereof that target semaphorin 3A (Sema3A). More specifically, anti-Sema3A antibodies and methods of use for the treatment of various diseases or disorders are disclosed.
    Type: Application
    Filed: January 26, 2024
    Publication date: October 10, 2024
    Inventors: Leo THOMAS, Rachel Rebecca BARRETT, Kristin Laura BOVAT, Rajkumar GANESAN, Priyanka GUPTA, Fei HAN, Dongmei LIU, Juergen PRESTLE, Sanjaya SINGH, Sathyadevi VENKATARAMANI, Helen Haixia WU, Nina ZIPPEL
  • Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof
    Patent number: 11884744
    Abstract: The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: January 30, 2024
    Assignees: Boehringer Ingelheim International GmbH, MacroGenics, Inc.
    Inventors: Sanjaya Singh, Qi Pan, Rachel Rebecca Barrett, Leslie S. Johnson, Pankaj Gupta, Sarah Low, Haixia Wu
  • COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF
    Publication number: 20230382988
    Abstract: The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Application
    Filed: March 6, 2023
    Publication date: November 30, 2023
    Inventors: Rachel Rebecca Barrett, Leslie S. Johnson, Sanjaya Singh, Kathleen Last-Barney, Daw-Tsun Shih, Patricia Giblin, Scott Brodeur, Nelamangala Nagaraja
  • Compound targeting IL-23A and TNF-alpha and uses thereof
    Patent number: 11680096
    Abstract: The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: June 20, 2023
    Assignees: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, MACROGENICS, INC.
    Inventors: Rachel Rebecca Barrett, Leslie S. Johnson, Sanjaya Singh, Kathleen Last-Barney, Daw-Tsun Shih, Patricia Giblin, Scott Brodeur, Nelamangala Nagaraja
  • ANTI-CD40 ANTIBODIES
    Publication number: 20220153857
    Abstract: The present invention related to new humanized antanogistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: February 7, 2022
    Publication date: May 19, 2022
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca BARRETT, Scott Ronald BRODEUR, Keith CANADA, Tobias Litzenburger, Sanjaya Singh
  • ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES
    Publication number: 20220144929
    Abstract: The present invention relates to antibodies and fragments thereof that target semaphorin 3A (Sema3A). More specifically, anti-Sema3A antibodies and methods of use for the treatment of various diseases or disorders are disclosed.
    Type: Application
    Filed: January 25, 2022
    Publication date: May 12, 2022
    Inventors: Leo THOMAS, Rachel Rebecca BARRETT, Kristin Laura BOVAT, Rajkumar GANESAN, Priyanka GUPTA, Fei HAN, Dongmei LIU, Juergen PRESTLE, Sanjaya SINGH, Sathyadevi VENKATARAMANI, Helen HAIXIA WU, Nina ZIPPEL
  • Anti-Sema3A antibodies and their uses for treating eye or ocular diseases
    Patent number: 11267880
    Abstract: The present invention relates to antibodies and fragments thereof that target semaphorin 3A (Sema3A). More specifically, anti-Sema3A antibodies and methods of use for the treatment of various diseases or disorders are disclosed.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: March 8, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Leo Thomas, Rachel Rebecca Barrett, Kristin Laura Bovat, Rajkumar Ganesan, Priyanka Gupta, Fei Han, Dongmei Liu, Juergen Prestle, Sanjaya Singh, Sathyadevi Venkataramani, Helen Haixia Wu, Nina Zippel
  • Anti-CD40 antibodies
    Patent number: 11242394
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: February 8, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca Barrett, Scott Ronald Brodeur, Keith Canada, Tobias Litzenburger, Sanjaya Singh
  • ANTI-IL-23 ANTIBODIES
    Publication number: 20210198355
    Abstract: The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: October 9, 2020
    Publication date: July 1, 2021
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca Barrett, Keith A. Canada, Katrina Mary Catron, Robert Copenhaver, Lee Edward Frego, Ernest Lee Raymond, Sanjaya Singh, Xiangyang Zhu
  • COMPOUND TARGETING IL-23A AND B-CELL ACTIVATING FACTOR (BAFF) AND USES THEREOF
    Publication number: 20210107998
    Abstract: The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Application
    Filed: October 22, 2020
    Publication date: April 15, 2021
    Inventors: Sanjaya SINGH, Qi PAN, Rachel Rebecca BARRETT, Leslie S. JOHNSON, Pankaj GUPTA, Sarah LOW, Haixia WU
  • COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF
    Publication number: 20210054065
    Abstract: The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Application
    Filed: August 26, 2020
    Publication date: February 25, 2021
    Inventors: Rachel Rebecca Barrett, Leslie S. Johnson, Sanjaya Singh, Kathleen Last-Barney, Daw-Tsun Shih, Patricia Giblin, Scott Brodeur, Nelamangala Nagaraja
  • ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES
    Publication number: 20200385446
    Abstract: The present invention relates to antibodies and fragments thereof that target semaphorin 3A (Sema3A). More specifically, anti-Sema3A antibodies and methods of use for the treatment of various diseases or disorders are disclosed.
    Type: Application
    Filed: May 8, 2020
    Publication date: December 10, 2020
    Inventors: Leo THOMAS, Rachel Rebecca BARRETT, Kristin Laura BOVAT, Rajkumar GANESAN, Priyanka GUPTA, Fei HAN, Dongmei LIU, Juergen PRESTLE, Sanjaya SINGH, Sathyadevi VENKATARAMANI, Helen HAIXIA WU, Nina ZIPPEL
  • Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof
    Patent number: 10844138
    Abstract: The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: November 24, 2020
    Assignees: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, MACROGENICS, INC.
    Inventors: Sanjaya Singh, Qi Pan, Rachel Rebecca Barrett, Leslie S. Johnson, Pankaj Gupta, Sarah Low, Haixia Wu
  • Compound targeting IL-23A and TNF-alpha and uses thereof
    Patent number: 10793629
    Abstract: The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: October 6, 2020
    Assignees: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, MACROGENICS, INC.
    Inventors: Rachel Rebecca Barrett, Leslie S. Johnson, Sanjaya Singh, Kathleen Last-Barney, Daw-Tsun Shih, Patricia Giblin, Scott Brodeur, Nelamangala Nagaraja
  • COMPOUND TARGETING IL-23A AND B-CELL ACTIVATING FACTOR (BAFF) AND USES THEREOF
    Publication number: 20190241678
    Abstract: The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Application
    Filed: February 18, 2019
    Publication date: August 8, 2019
    Inventors: Sanjaya SINGH, Qi Pan, Rachel Rebecca Barrett, Leslie S. Johnson, Pankaj Gupta, Sarah Low, Haixia Wu
  • ANTI-CD40 ANTIBODIES
    Publication number: 20190169301
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: July 10, 2018
    Publication date: June 6, 2019
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca Barrett, Scott Ronald Brodeur, Keith Canada, Tobias Litzenburger, Sanjaya Singh
  • ANTI-IL-23 ANTIBODIES
    Publication number: 20190144534
    Abstract: The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: January 25, 2019
    Publication date: May 16, 2019
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca Barrett, Keith A. Canada, Katrina Mary Catron, Robert Copenhaver, Lee Edward Frego, Ernest Lee Raymond, Sanjaya Singh, Xiangyang Zhu
  • Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof
    Patent number: 10280231
    Abstract: The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: May 7, 2019
    Assignees: Boehringer Ingelheim International GmbH, MacroGenics, Inc.
    Inventors: Sanjaya Singh, Qi Pan, Rachel Rebecca Barrett, Leslie S. Johnson, Pankaj Gupta, Sarah Low, Haixia Wu
  • Anti-IL-23 antibodies
    Patent number: 10202448
    Abstract: The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: February 12, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca Barrett, Keith A. Canada, Katrina Mary Catron, Robert Copenhaver, Lee Edward Frego, Ernest Lee Raymond, Sanjaya Singh, Xiangyang Zhu
  • COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF
    Publication number: 20190016794
    Abstract: The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Application
    Filed: August 1, 2018
    Publication date: January 17, 2019
    Inventors: Rachel Rebecca Barrett, Leslie S. Johnson, Sanjaya Singh, Kathleen Last-Barney, Daw-Tsun Shih, Patricia Giblin, Scott Brodeur, Nelamangala Nagaraja